Novartis releases long-term data for SMA gene therapy
Long-term follow-up study data for Novartis’ one-time gene therapy for spinal muscular atrophy has shown promising milestone achievements.
Source: europeanpharmaceuticalreview.com
Stay updated with breaking news from Clinical Development Analytics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Long-term follow-up study data for Novartis’ one-time gene therapy for spinal muscular atrophy has shown promising milestone achievements.